NCT06597734撤回2 期
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
详细描述
Primary Objectives To determine the overall response rate of olutasidenib in combination with investigator's choice of HMA in patients with IDH1-mutated higher-risk MDS/CMML or advanced MPN Secondary Objectives
The secondary objectives of this study are:
- To evaluate the rates of complete remission (CR) and median duration of CR
- To ascertain the safety and tolerability of olutasidenib with HMA in this participant population
- To determine survival including overall survival (OS), progression-free survival (PFS), and duration of response (DOR) To analyze reduction in IDH1 clone size Exploratory Objectives
- To examine overall response rate of patients previously exposed to venetoclax
- To investigate global gene expression profiles, DNA methylation profiles, and other potential prognostic markers to explore predictors of antitumor activity and/or resistance to treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically proven higher-risk MDS/CMML or advanced MPN
- •MDS participants must have International Prognostic Scoring System (IPSS) intermediate-2- or high-risk disease or Revised IPSS (IPSS-R) score >= 3.5 or Molecular IPSS (IPSS-M) moderate high-, high-, or very high-risk disease or bone marrow blast percentage.
- •CMML patients must have CPSS-Mol int-1, int-2, or high-ris disease (Elena C et al, Blood 2016)
- •Advanced MPN is defined as bone marrow blast percentage >=/=10%.
- •Participants on the treatment-naive arm must not have received a prior HMA. Agents such as growth factors (e.g. erythropoietin stimulating agents, luspatercept, eltrombopag, granulocyte colony stimulating factors), cyclosporine, and/or hydroxyurea are allowed.
- •Patients on the previously-treated arm must have received a prior HMA and/or ivosidenib. Prior stem cell transplantation in allowed>
- •Participants must have a documented IDH1 mutation
- •Patients with previously-treated MDS must be ineligible to receive treatment with ivosidenib or have progressed on treatment with ivosidenib.
- •Participants >=/= 18 years old
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Appendix A)
- •Acceptable liver function
- •Bilirubin /= 50 mL/min (as assessed by Cockcroft-Gault, MDRD, or CKD-Epi validated measures)
- •Negative serum or urine pregnancy test if female of childbearing potential c. For fertile men and women, agreement to use highly effective contraceptive methods for the duration of study participation and 90 days after the last dose of study medication d. Agreement for male participants not to donate sperm and for female participants of childbearing potential not to donate ova during the study and for 90 days after the final dose of study drug
- •Ability and willingness to sign informed consent prior to beginning study and undergoing procedures
排除标准
- •Participants unable to swallow oral medications, or participants with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption
- •Participants with any concurrent uncontrolled clinically significant medical condition, including life-threatening severe infection or psychiatric illness, which could place the participant at unacceptable risk of study treatment
- •Patients must have discontinued prior chemotherapy at least 1 week prior to the start of study treatment. Patients with MPN must be off JAK inhibitors at the start of study treatment
- •Patients with active graft-versus-host-disease (GVHD) status post stem cell transplantation, including active chronic GVHD requiring topical therapy. Patients must have discontinued calcineurin inhibitors at least 4 weeks prior to the start of study treatment
- •Known active hepatitis B (HBV) or hepatitis C (HCV) or HIV infection
- •Pregnant or nursing women or women of childbearing potential not using highly effective contraception; male participants not using highly effective contraception
- •Participants with white blood cell count > 25 x109/L Note: hydroxyurea use is permitted to meet this criterion
- •Unwillingness or inability to comply with procedures either required in this protocol or considered standard of care
研究组 & 干预措施
Olutasidenib+Azacitidine-IV or SubQ
Experimental
Participants will take capsules of olutasidenib 2 times each day while you are on study. Each dose should be taken about 12 hours apart at least 1 hour before or 2 hours after a meal. Azacitidine IV or Sub Q for 7 days every 28 days.
干预措施: Olutasidenib (Drug)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.Myelodysplastic SyndromesClonal Cytopenia of Undetermined SignificanceChronic Myelomonocytic LeukemiaNCT06566742M.D. Anderson Cancer Center15
招募中
2 期
Study of Olutasidenib and Temozolomide in HGGHigh Grade GliomaAstrocytoma, Grade IIIAstrocytoma, Grade IVDiffuse Intrinsic Pontine GliomaWHO Grade III GliomaWHO Grade IV GliomaMetastatic Brain TumorDiffuse Midline Glioma, H3 K27M-MutantThalamus TumorIDH1 MutationIDH1 R132IDH1 R132CIDH1 R132HIDH1 R132SIDH1 R132GIDH1 R132LOligodendrogliomaAstrocytomaSpinal TumorNCT06161974Rigel Pharmaceuticals60
招募中
2 期
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian CancerOvarian CancerNCT05983276Loyola University40
已完成
2 期
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid LeukemiaAMLNCT03118466Massachusetts General Hospital41
已完成
2 期
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT02135133Dana-Farber Cancer Institute27